Story · Medicine & Biotech
Thomas Hope: Combining Immunotherapy and PRRT to Improve Outcomes in High-Grade NETs
1 outlet · first reported by OncoDaily on
Thomas Hope, Professor in Residence at University of California, shared on LinkedIn: “Can immunotherapy improve PRRT in high-grade NETs? Nicholas Fidelman led our pilot study combining pembrolizumab with 177Lu-DOTATATE, which (OncoDaily)
Coverage, in order
-
Thomas Hope: Combining Immunotherapy and PRRT to Improve Outcomes in High-Grade NETsThomas Hope, Professor in Residence at University of California, shared on LinkedIn: “Can immunotherapy improve PRRT in high-grade NETs? Nicholas Fidelman led our pilot study combining pembrolizumab with 177Lu-DOTATATE, which
Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.